Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug shows promise for Long-Term cholesterol control

NCT ID NCT05413135

Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at the long-term safety of a drug called ARO-APOC3 in adults with dyslipidemia (abnormal fat levels in the blood). Participants who completed a previous 12-month study could continue receiving the drug every 3 or 6 months. The goal was to see if the drug remains safe over time and continues to lower triglycerides, a type of blood fat.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ARO-APOC3 injection
What this could lead to
If successful, this could provide a long-term treatment option to lower triglycerides and manage dyslipidemia, reducing heart disease risk.
What could go wrong
This is an early-phase extension study, so long-term safety and effectiveness are not yet proven. Side effects or lack of sustained benefit are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

418 people

The number who actually took part.

Started

Jul 2022

Finished

Sep 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults who are nonpregnant, nonlactating and do not plan to become pregnant during the study * Able and willing to provide written informed consent * Completed the 48-week study treatment period in the parent study Exclusion Criteria: * Subject was permanently discontinued from ARO-APOC3 in the parent study due to elevated glycated hemoglobin (HbA1c), aspartate aminotransferase (AST) or alanine aminotransferase (ALT) * Any new condition or worsening of existing condition or any other situation that would make the subject unsuitable for enrollment, could interfere with the subject participating in or completing the study, would make it difficult to comply with protocol requirements or put the subject at additional safety risk * Unwilling to limit alcohol consumption to within moderate limits for the duration of the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyslipidemias are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dyslipidemias hyperlipidemia inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyslipidemias

Contacts and locations

Locations

  • Clincal Research Site 4

    Boca Raton, Florida, 33434, United States

  • Clinical Research Site 1

    Beverly Hills, California, 90211, United States

  • Clinical Research Site 10

    Pembroke Pines, Florida, 33024, United States

  • Clinical Research Site 11

    Port Orange, Florida, 32127, United States

  • Clinical Research Site 12

    Dunwoody, Georgia, 30338, United States

  • Clinical Research Site 13

    Minneapolis, Minnesota, 55455, United States

  • Clinical Research Site 14

    Tupelo, Mississippi, 38801, United States

  • Clinical Research Site 15

    Omaha, Nebraska, 68114, United States

  • Clinical Research Site 16

    Las Vegas, Nevada, 89121, United States

  • Clinical Research Site 17

    Long Island City, New York, 11106, United States

  • Clinical Research Site 18

    New Windsor, New York, 12553, United States

  • Clinical Research Site 19

    New York, New York, 10029, United States

  • Clinical Research Site 2

    Northridge, California, 91325, United States

  • Clinical Research Site 20

    Morehead City, North Carolina, 28557, United States

  • Clinical Research Site 21

    Fargo, North Dakota, 58104, United States

  • Clinical Research Site 22

    Marion, Ohio, 43302, United States

  • Clinical Research Site 23

    Maumee, Ohio, 43537, United States

  • Clinical Research Site 24

    Oklahoma City, Oklahoma, 73135, United States

  • Clinical Research Site 25

    Greenville, South Carolina, 29607, United States

  • Clinical Research Site 26

    Chattanooga, Tennessee, 37421, United States

  • Clinical Research Site 27

    Houston, Texas, 77030, United States

  • Clinical Research Site 28

    Houston, Texas, 77099, United States

  • Clinical Research Site 29

    Houston, Texas, 77002, United States

  • Clinical Research Site 3

    Palm Springs, California, 92292, United States

  • Clinical Research Site 30

    San Antonio, Texas, 78249, United States

  • Clinical Research Site 31

    Manassas, Virginia, 20110, United States

  • Clinical Research Site 32

    Camperdown, New South Wales, 2050, Australia

  • Clinical Research Site 33

    Milton, Queensland, 4068, Australia

  • Clinical Research Site 34

    Sippy Downs, Queensland, 4556, Australia

  • Clinical Research Site 35

    Adelaide, South Australia, 5000, Australia

  • Clinical Research Site 36

    Clayton, Victoria, 3168, Australia

  • Clinical Research Site 37

    Joondalup, Washington, 6027, Australia

  • Clinical Research Site 38

    Nedlands, Washington, 6009, Australia

  • Clinical Research Site 39

    Concord, Ontario, L4K4M2, Canada

  • Clinical Research Site 40

    London, Ontario, N6A 5A5, Canada

  • Clinical Research Site 41

    Chicoutimi, Quebec, G7H 7K9, Canada

  • Clinical Research Site 43

    Montreal, Quebec, H2W 1R7, Canada

  • Clinical Research Site 44

    Québec, Quebec, G1G 3Z4, Canada

  • Clinical Research Site 46

    Balatonfüred, H-8230, Hungary

  • Clinical Research Site 47

    Békéscsaba, 5600, Hungary

  • Clinical Research Site 48

    Debrecen, 4032, Hungary

  • Clinical Research Site 49

    Gyöngyös, 3200, Hungary

  • Clinical Research Site 5

    Fort Lauderdale, Florida, 33308, United States

  • Clinical Research Site 50

    Komárom, H-2900, Hungary

  • Clinical Research Site 51

    Nyíregyháza, 4400, Hungary

  • Clinical Research Site 53

    Amsterdam, 1105 AZ, Netherlands

  • Clinical Research Site 54

    Sneek, 8601 ZR, Netherlands

  • Clinical Research Site 55

    Zwijndrecht, 3331LZ, Netherlands

  • Clinical Research Site 56

    Christchurch, 8011, New Zealand

  • Clinical Research Site 57

    Christchurch, 8013, New Zealand

  • Clinical Research Site 58

    Papatoetoe, Aukland, 2025, New Zealand

  • Clinical Research Site 59

    Bydgoszcz, 85-605, Poland

  • Clinical Research Site 6

    Miami, Florida, 33173, United States

  • Clinical Research Site 60

    Oświęcim, 32-600, Poland

  • Clinical Research Site 61

    Poznan, 61-655, Poland

  • Clinical Research Site 62

    Rzeszów, 35-055, Poland

  • Clinical Research Site 63

    Lodz, 94 046, Poland

  • Clinical Research Site 64

    Lodz, 93-338, Poland

  • Clinical Research Site 8

    Miami, Florida, 33155, United States

  • Clinical Research Site 9

    Miami Springs, Florida, 33166, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.